TORONTO, ON (August 10, 2015) — Toronto-based law firm Aird & Berlis LLP (A&B) has become the sponsoring legal partner to the University of Toronto Early-Stage Technology Program (UTEST).
This partnership was covered in TechVibes, Law Times and the Financial Post's Legal Post blog.
UTEST is a 12-month incubation and acceleration program co-managed by the University of Toronto (U of T) and MaRS Innovation that allows selected U of T-affiliated early-stage startup companies to incorporate, use office space, receive mentorship and access $30,000 ...
MaRS Innovation staff and WaveCheck Campaign Co-directors Dr. Fazila Seker and Elizabeth Monier-Williams spoke with the CBC's Colleen Ross about the process of crowdfunding WaveCheck's partner-based clinical studies on "The World This Weekend."
The radio segment, called "Crowdfunding Science," aired on January 25, 2014 and discussed the lack of funding researchers have access to for commercialization, making it harder to advance research that could be helping people in a variety of industries.
To listen to the full interview, click here.
WaveCheck's crowdfunding campaign is an example of ...
Dr. Andrew (Andy) Sinclair, OtoSim’s CEO, was interviewed by PharmaBoadroom.com on October 10, 2013 to discuss the company’s success and plans for the future.
OtoSim's otoscopy training device is revolutionizing the way medical students, teachers and nurses perfect otoscopy techniques. The invention, developed by Doctors Vito Forte and Paolo Campisi at the Hospital for Sick Children (SickKids), provides them with a device that simulates the structure of an actual ear rather than only reading techniques from a textbook.
The article highlights how effective ...
Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership
TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership.
Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area.
This announcement was covered by BetaKit.
His technology generates cell lines with improved protein production and survival properties, important in the ...
Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centres, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health.
Read the original release via The National Post or in French. MaRS Innovation's November 25 announcement about the partnership is also available.
This story was covered by GEN: Genetic Engineering Biotechnology News.
Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in ...
Canadian commercialization and entrepreneurial programs helping scientists and researchers bring their products to market are the focus of a recent article in Nature Journal and on nature.com.
Posted online on October 2, 2013, the article explains how the Centres of Excellence in Commercialization and Research (CECR) programme, and specifically MaRS Innovation, develop research and put it into practice:
"MARS Innovation and its sister organization MARS Discovery District are not-for-profit organizations that are tightly integrated in Canadian research commercialization. They are based in a heritage building ...
VitalHub is building on its success in redefining how doctors access patient data by partnering with Box, which announced 13 new partnerships with companies, including VitalHub.
Together, their technology will work across web and mobile devices to help healthcare organizations work with, share and collaborate using information.
Invented at Toronto's Mount Sinai Hospital in the IT Department, VitalHub was created to effectively manage patient data through a platform allowing clinicians to rapidly access comprehensive, relevant patient information gathered from multiple disparate clinical information systems.
The VitalHub Server platform sits ...
Xagenic’s financing round to test platform and first diagnostic assay, continue product development and begin FDA submission
Toronto, ON (December 2, 2013) — MaRS Innovation’s first start-up company, Xagenic Inc., is developing the first lab-free molecular diagnostic platform with a 20-minute time-to-result based on University of Toronto research by Professors Shana Kelley and Edward Sargent.
Today, Xagenic announced it has successfully closed a Series B financing round totaling $20 million. New investor Domain Associates, LLC, led the round, joined by existing investors who ...